...
首页> 外文期刊>Plastic and reconstructive surgery >A Retrospective Case Series Reporting the Outcomes of Avance Nerve Allografts in the Treatment of Peripheral Nerve Injuries
【24h】

A Retrospective Case Series Reporting the Outcomes of Avance Nerve Allografts in the Treatment of Peripheral Nerve Injuries

机译:回顾性案例系列报告了海绵神经损伤治疗中的AVANCE神经异种移植物的结果

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Acellular nerve allografts are a viable treatment modality for bridging nerve gaps. Several small studies have demonstrated results equal to those of autologous grafts; however, there is information lacking with regard to outcomes for wider indications. The authors evaluated the outcomes of patients treated with a nerve allograft in a variety of clinical situations. Methods: A retrospective chart analysis was completed between April of 2009 and October of 2017. Inclusion criteria were age 18 years or older at the time of surgery and treatment with a nerve allograft. Patients were excluded if they had not been followed up for a minimum of 6 months. The modified Medical Research Council Classification was used to monitor motor and sensory changes in the postoperative period. Results: Two hundred seven nerve allografts were used in 156 patients; of these, 129 patients with 171 nerve allografts fulfilled the inclusion criteria. Seventy-seven percent of patients achieved a sensory outcome score of S3 or above and 36 percent achieved a motor score of M3 or above. All patients with chronic pain had improvement of their symptoms. Graft length and diameter were negatively correlated with reported outcomes. One patient elected to undergo revision surgery, and the original graft was shown histologically to have extensive central necrosis. Anatomically, allografts used for lower limb reconstruction yielded the poorest results. All chronic patients had a significantly lower postoperative requirement for analgesia, and allografts were effective in not only reducing pain but also restoring a functional level of sensation. Conclusions: This study supports the wider application of allografts in managing nerve problems. However, caution must be applied to the use of long grafts with larger diameters. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
机译:背景:细胞神经同种异体移植物是用于桥接神经间隙的可行治疗方式。几项小型研究表明,结果等于自体移植物的结果;然而,关于更广泛的适用性的结果缺乏信息。作者评估了在各种临床情况下用神经同种异体移植治疗的患者的结果。方法:2017年4月至10月在2017年4月之间完成了回顾性图表分析。纳入标准在手术时期或患有神经同种异体移植的治疗时间为18岁或以上。如果患者尚未跟进至少6个月,则被排除在外。修改后的医学研究委员会分类用于监测术后期间的电机和感官变化。结果:156名患者使用了两百七神经同种异体移植物;其中129例171名神经同种异体移植物符合纳入标准。百分之七十七名患者实现了S3或以上的感觉结果得分,36%实现了M3或更高的运动得分。所有慢性疼痛的患者都有改善它们的症状。移植物长度和直径与报告的结果负相关。一名患者选择进行修正手术,并且原始移植物在组织学上显示,以具有广泛的中央坏死。解剖学上,用于较低肢体重建的同种异体移植物产生了最糟糕的结果。所有慢性患者对镇痛的术后要求显着降低,同种异体移植物不仅有效减少疼痛,而且还有效,而且还恢复了功能水平的感觉。结论:本研究支持对同种异体移植的更广泛应用于管理神经问题。但是,必须谨慎地应用于使用较大直径的长移植物。临床问题/证据水平:治疗,IV。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号